Gene expression profiling of melanoma cells – searching the haystack by Brafford, Patricia & Herlyn, Meenhard
BioMed  Central
Page 1 of 2
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Commentary
Gene expression profiling of melanoma cells – searching the 
haystack
Patricia Brafford* and Meenhard Herlyn
Address: The Wistar Institute, Philadelphia PA 19104, USA
Email: Patricia Brafford* - brafford@wistar.upenn.edu; Meenhard Herlyn - herlynm@wistar.upenn.edu
* Corresponding author    
Abstract
Cancer is being increasingly recognized as a very heterogeneous disease, both within an individual
tumor and within a tumor type and among tumor types. This heterogeneity is manifested both at
the genetic and phenotypic level and determines the progression of disease and response to
therapy. It is possible to see the heterogeneity in examples of differential disease progression and
response to therapy of the same tumor type, as morphology does not always reveal underlying
biology. The diagnosis of tumors by histopathological and morphological criteria cannot fully
account for the variability seen in prognosis and therapy outcome. Here we review some recent
concepts that have emerged from the genetic analysis of metastatic melanoma.
Commentary
Cancer is being increasingly recognized as a very heteroge-
neous disease, both within an individual tumor and
within a tumor type and among tumor types. This hetero-
geneity is manifested both at the genetic and phenotypic
level and determines the progression of disease and
response to therapy. It is possible to see the heterogeneity
in examples of differential disease progression and
response to therapy of the same tumor type, as morphol-
ogy does not always reveal underlying biology. The diag-
nosis of tumors by histopathological and morphological
criteria cannot fully account for the variability seen in
prognosis and therapy outcome. A classic example of this
heterogeneity is diffuse large B cell lymphoma (DLBCL)
morphologically defined as one tumor type but only 40%
of patients respond to treatment suggesting there are at
least two distinct tumor groups. Alizadeh et. al. performed
microarrays on DLCBL to assess gene expression profiles
and identified several genetically distinct groups that cor-
related with differential survival rates [[1], reviewed in
[2]]. Genome wide screening technology such as microar-
ray offer the potential to diagnose, prognose and develop
new therapeutic strategies for cancers based on grouping
by genetic signature.
Whereas previously, it was possible only to study one or a
few genes at a time, microarray technology allows the
simultaneous assessment of the expression of thousands
of genes within a cell population at a single time. By look-
ing at the full spectrum of the genetic contribution within
a tumor, microarray technology has furthered our under-
standing of the complexity in terms of tumor subclassifi-
cation. The advantage of a global gene expression analysis
is that it assesses many genes within a sample at a given
timepoint and allows comparison to a myriad of other
samples. This has resulted in the improved classification
of tumors, identification of potential new biomarkers,
and detection of possible therapeutic targets as in DLBCL.
In addition, the same gene expression data can be reana-
lyzed according to a user defined phenotype or without
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bias while looking for patterns in the data that correlate
with a phenotype such as progression, prognosis, or treat-
ment outcome. As data analysis and data mining become
more sophisticated, the information acquired will provide
scientists and clinicians with a significant improvement in
correlating patient data with tumor diagnosis and ena-
bling us to better select patient groups who will respond
(or not respond) to therapy. Microarray technology has
become the best hope in developing a global and accurate
assessment of the tumor type and all its complexity. How-
ever, the road to achieve this goal will be long and hard
because we have to learn to ask the right questions, select
the appropriate patients, collect their material and then
verify the initial results.
Clinical pathological analysis cannot predict clinical out-
come or metastatic potential of melanoma, a very hetero-
geneous cancer with an unpredictable progression rate. In
a previous issue, Wang et. al. performed gene expression
analysis on RNA from a number of human solid tumor
lesions, including melanoma [3]. In their comparison
they showed that it is possible to identify tumor specific
gene expression profiles which can rapidly aid in tumor
identification and classification. In addition, the study
identified commonly expressed genes between melanoma
and Renal Cell carcinoma, both known to be responsive
clinically to IL-2 treatment, allowing for comparison of
immunologically related genes to identify common
response pathways. Gene expression profiles of
melanoma lesions can also be used for prognosis by strat-
ifying patients based on risk and thus identifying sub-
types. For example, an early study by Clark et. al. assessed
the gene expression differences of metastatic versus non-
metastatic melanoma cell lines, identifying a metastatic
profile which was linked to the small GTPase RhoC [4].
Bittner et. al. performed a more comprehensive array anal-
ysis of 31 cutaneous melanomas and identified a major
cluster of melanoma samples [5]. Further, the authors
were able to verify the validity of the cluster by correlating
the melanomas within the cluster to reduced motility,
invasive ability, and vasculogenic mimicry potential in
vitro. This showed that lesions can be stratified into sub-
types by gene expression analysis. Further, microarray
gene expression data can be used to define responders and
non-responders to known anti-cancer treatments prospec-
tively or retrospectively. By combining clinical data with
microarray data, it will be possible to predict patient
response based on gene expression profile or biomarkers,
which may allow for better, more targeted therapies to be
selected. This new information will lead to improved
treatments and prolonged survival for cancer patients.
DNA microarray technology may help us understand the
complex pathogenesis of melanoma and will allow us to
determine the role of the different genetic profiles in
determining different disease outcomes. From this we will
be able to identify new biomarkers, leading to the devel-
opment of more pathologically relevant models. To
achieve better prediction for optimal treatment strategies,
microarray studies as presented here are only the begin-
ning of a long road, in which we need to drastically par
down the markers to be tested. We need to verify and val-
idate biomarker candidates in ways that go beyond the
capacity of individual laboratories. Instead we need to
establish consortia of scientists from bioinformatics and
computational biology, who team up with oncologists,
pathologists, and immunobiologists. Any selected
biomarker requires validation in independent multi-
center analyses. Once the appropriate tools and infrastruc-
tures are on hand, we can select better new treatment
modalities and may realize that previously unsuccessful
regimens would have shown more success, if we would
have know how to select most appropriate patients. We
have to start now to develop the groundwork for such
multidisciplinary, multi-institutional work that will chal-
lenge us in the years to come.
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